Antitumour activity of Salmonella typhimurium VNP20047 in B16(F10) murine melanoma model.
Jazowiecka-Rakus
Joanna
J
Department of Molecular Biology, Centre of Oncology, Maria Skłodowska-CurieMemorial Institute, Gliwice, Poland. jjazowiecka@io.gliwice.pl
Szala
Stanisław
S
D000818:Animals; D000963:Antimetabolites / Q000627:therapeutic use; D015169:Colony Count, Microbial; D043525:Cytosine Deaminase / Q000235:genetics; D004926:Escherichia coli / Q000201:enzymology / Q000235:genetics; D005437:Flucytosine / Q000627:therapeutic use; D005798:Genes, Bacterial; D015316:Genetic Therapy / Q000009:adverse effects / Q000379:methods*; D007249:Inflammation / Q000209:etiology / Q000473:pathology; D008099:Liver / Q000382:microbiology / Q000473:pathology; D008546:Melanoma, Experimental / Q000382:microbiology / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D012486:Salmonella typhimurium / Q000235:genetics* / Q000254:growth & development / Q000302:isolation & purification / Q000472:pathogenicity; D014774:Virulence / Q000235:genetics
D000963:Antimetabolites; D005437:Flucytosine; D043525:Cytosine Deaminase